PriceTargets.com logo

Biotricity - BTCY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.39 As of 09/6/2024 01:00 AM ET
▼ -0.01 (-2.52%)

This chart shows the closing price for BTCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biotricity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTCY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Biotricity in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.39.

This chart shows the closing price for BTCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Biotricity. This rating has held steady since February 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/15/2023HC WainwrightReiterated RatingBuy$12.00
7/15/2022Lake Street CapitalLower Target$30.00 ➝ $24.00
7/15/2022Maxim GroupDowngradeBuy ➝ Hold
3/7/2022Lake Street CapitalInitiated CoverageBuy$30.00
11/23/2021HC WainwrightInitiated CoverageBuy$36.00
11/5/2021Maxim GroupReiterated RatingBuy$42.00
10/22/2021Maxim GroupReiterated RatingBuy$36.00
9/10/2021Maxim GroupReiterated RatingBuy$36.00
7/1/2021Northland SecuritiesInitiated CoverageOutperform$42.00
7/1/2021Noble FinancialInitiated CoverageOutperform$42.00
(Data available from 9/8/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/11/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/12/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/11/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Biotricity logo
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Read More

Today's Range

Now: $0.39
Low: $0.37
High: $0.40

50 Day Range

MA: $0.61
Low: $0.39
High: $0.90

52 Week Range

Now: $0.39
Low: $0.35
High: $2.43

Volume

2,463 shs

Average Volume

79,330 shs

Market Capitalization

$8.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Biotricity?

The following Wall Street research analysts have issued research reports on Biotricity in the last twelve months:
View the latest analyst ratings for BTCY.

What is the current price target for Biotricity?

0 Wall Street analysts have set twelve-month price targets for Biotricity in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Biotricity in the next year.
View the latest price targets for BTCY.

What is the current consensus analyst rating for Biotricity?

Biotricity currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BTCY.

What other companies compete with Biotricity?

Other companies that are similar to Biotricity include Precision Optics, IRIDEX, ReWalk Robotics, SurgePays and Outset Medical. Learn More about companies similar to Biotricity.

How do I contact Biotricity's investor relations team?

The company's listed phone number is (650) 832-1626 and its investor relations email address is [email protected]. The official website for Biotricity is www.biotricity.com. Learn More about contacing Biotricity investor relations.